Related Experiment Video
Updated: Jan 11, 2026
The Soft Agar Colony Formation Assay
Published on: October 27, 2014
NHWD-870 suppresses tumor proliferation via the BRD4/STRADA/CCND1 axis in small cell lung cancer
Linrui Ma1, Xiangyu Zhang2, Shidong Xu1
1Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
Background:
Small cell lung cancer (SCLC) is a highly aggressive malignancy with poor prognosis and limited therapeutic options. The lack of effective targeted therapies for SCLC is a major limitation of this field. Bromodomain and Extra-Terminal (BET) inhibitors have emerged as a promising class of anticancer agents. This study aimed to evaluate the preclinical efficacy and mechanism of action of NHWD-870, a novel BET inhibitor targeting BRD4, in SCLC.
Method:
The therapeutic effects of NHWD-870 on SCLC have been validated through compassionate use. The anti-tumor effects of NHWD-870 were explored using in vitro and in vivo models. CCK-8 assays and flow cytometry were utilized to examine cell viability, apoptosis, and mechanisms of cell cycle arrest. The in vivo effectiveness of NHWD-870 was evaluated using cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) models of SCLC. Mechanistic studies involving RNA sequencing, Western blotting, qPCR, and transfection were conducted to investigate and confirm the underlying mechanisms of NHWD-870.
Result:
Our study observed the efficacy of NHWD-870 in a patient with SCLC. NHWD-870 demonstrated robust anti-tumor activity against SCLC in both in vitro and in vivo models, effectively halting tumor growth, inducing apoptosis, and disrupting the cell cycle. RNA sequencing confirmed that the cell cycle is its primary pathway of action, with BRD4, STRADA, and CCND1 identified as key targets.
Conclusion:
NHWD-870 exhibits anti-tumor activity both in vitro and in vivo against SCLC, primarily by regulating the BRD4/STRADA/CCND1 axis and inhibiting the transition of the cell cycle from the G1 phase to the S phase. These findings highlight the therapeutic potential of NHWD-870 as a novel BET inhibitor for SCLC treatment and provide a molecular basis for further clinical development.
Insights
NHWD-870, a novel Bromodomain and Extra-Terminal (BET) inhibitor, shows significant anti-tumor activity against small cell lung cancer (SCLC). It effectively halts tumor growth and induces apoptosis by targeting the BRD4/STRADA/CCND1 axis and cell cycle progression.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Small cell lung cancer (SCLC) is an aggressive malignancy with limited treatment options.
- Targeted therapies for SCLC are lacking, necessitating novel therapeutic strategies.
- Bromodomain and Extra-Terminal (BET) inhibitors represent a promising class of anticancer agents.
Purpose of the Study:
- To evaluate the preclinical efficacy of NHWD-870, a novel BET inhibitor targeting BRD4, in SCLC.
- To elucidate the mechanism of action of NHWD-870 in SCLC models.
- To assess the therapeutic potential of NHWD-870 for SCLC treatment.
Main Methods:
- In vitro and in vivo studies using SCLC cell lines and xenograft models (CDX and PDX).
- Assays for cell viability, apoptosis, and cell cycle analysis (CCK-8, flow cytometry).
- Mechanistic investigations using RNA sequencing, Western blotting, and qPCR to identify key targets and pathways.
Main Results:
- NHWD-870 demonstrated significant anti-tumor activity in both in vitro and in vivo SCLC models.
- The drug effectively inhibited tumor growth, induced apoptosis, and caused cell cycle arrest.
- RNA sequencing identified the cell cycle as the primary pathway affected, with BRD4, STRADA, and CCND1 as key targets.
Conclusions:
- NHWD-870 exhibits potent anti-tumor effects against SCLC through in vitro and in vivo mechanisms.
- The drug functions by regulating the BRD4/STRADA/CCND1 axis, inhibiting G1 to S phase cell cycle transition.
- NHWD-870 shows therapeutic potential as a novel BET inhibitor for SCLC, warranting further clinical development.
More Related Videos
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Related Concept Videos
02:23Abnormal Proliferation
02:34Inhibition of Cdk Activity
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:33Hedgehog Signaling Pathway
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...